Andrew Yee, MD, introduces the discussion by reviewing treatment challenges, patient education, and decision-making in ...

Multiple myeloma (MM) is characterized by a significant heterogeneity at the molecular level. The first level is the chromosomal one. Although cytogenetics is difficult to assess in MM, patients can ...

A recent review summarized the current knowledge and treatment paradigm of multiple myeloma, including recent advances and challenges in nanomedicine. Multiple myeloma (MM) management has changed in ...

In the cancer type multiple myeloma, the malignant cells differ significantly from normal cells regarding the layer of chemical “tags” on DNA and proteins that control whether genes are turned on or ...

Multiple myeloma is the second most commonly diagnosed type of blood cancer (after lymphoma). But it’s still relatively uncommon. Around the world, there were about 180,000 new cases in 2022. That ...

Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple myeloma. In a new preclinical study, they demonstrate that a dual treatment ...

Multiple myeloma is a chronic (long-term) blood cancer that affects plasma cells made in the bone marrow, which is spongy tissue found inside bones. While people with multiple myeloma can live for ...

Multiple myeloma is an uncommon cancer affecting plasma cells in the bone marrow. Tumors in the bones and other organs can cause the cells to grow out of control. A complication of this cancer is ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...